Isis Pharma, CHDI renew HD drug pact

As per the terms of the agreement, CHDI will fund Isis to identify and conduct IND-enabling studies on an antisense drug targeting the huntingtin gene.

Additionally, Isis is eligible to be reimbursed by CHDI for approximately $2m of HD research-related expenses Isis incurred after the earlier collaboration ended in 2010.

Both the firms expect to continue collaboration on the clinical development of drugs arising from the collaboration.

CHDI Chemistry director Alex Kiselyov said Antisense oligonucleotides show considerable potential in this regard and they are excited to work further with Isis to develop this approach as a therapy for HD.